Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice

Abstract Background Cardiovascular outcome trials in high-risk patients showed that some GLP-1 receptor agonists (GLP-1RA), but not dipeptidyl-peptidase-4 inhibitors (DPP-4i), can prevent cardiovascular events in type 2 diabetes (T2D). Since no trial has directly compared these two classes of drugs,...

Full description

Bibliographic Details
Main Authors: Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Cardiovascular Diabetology
Subjects:
Observational
Registry, outcome
Epidemiology
Drug therapy
Online Access:http://link.springer.com/article/10.1186/s12933-020-01049-w

Internet

http://link.springer.com/article/10.1186/s12933-020-01049-w

Similar Items